S&P 500

5.277,51

0,80%

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

NVS Novartis AG

103,13

0,00 (0,00%)

Vor Marktöffnung

Zuletzt aktualisiert: 12:56:48

Verzögert um 15 Minuten

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

0001370368-24-000004.txt

Novartis (NYSE:NVS)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Novartis (NYSE:NVS)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

News Novartis AG

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
Samstag 25 Mai 2024 (1 Woche vor) • PR Newswire (US)

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Samstag 25 Mai 2024 (1 Woche vor) • PR Newswire (US)

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Freitag 24 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 22 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
Dienstag 7 Mai 2024 (4 Wochen vor) • GlobeNewswire Inc.

Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News
Dienstag 23 April 2024 (1 Monat vor) • IH Market News

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Montag 15 April 2024 (2 Monate vor) • PR Newswire (US)

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Donnerstag 11 April 2024 (2 Monate vor) • GlobeNewswire Inc.

Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News
Mittwoch 10 April 2024 (2 Monate vor) • IH Market News

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
Samstag 6 April 2024 (2 Monate vor) • PR Newswire (US)

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Donnerstag 15 Februar 2024 (4 Monate vor) • Edgar (US Regulatory)

Form SC TO-C - Written communication relating to an issuer or third party
Dienstag 6 Februar 2024 (4 Monate vor) • Edgar (US Regulatory)

Weitere Novartis AG News-Artikel

AMEX

GNOV

FT Vest US Equity Modera...

USOTC

TNLIF

Trainline (PK)

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

NVS Novartis AG

News Novartis AG

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

NVS Novartis AG

News Novartis AG

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen